Summary: A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to the general population. Even after accounting for other mental health disorders and…
Tag: psychopharmacology
Psychedelics Reduce Anxiety Without Hallucinations
Summary: New research has pinpointed the specific brain region and neuron type responsible for reducing anxiety using the psychedelic drug DOI, without triggering hallucinations. The study revealed that DOI targets…
High Doses of ADHD Meds Linked to Increased Psychosis Risk
Summary: Adults taking high doses of amphetamine-based medications for ADHD, such as Adderall, face a five-fold increased risk of developing psychosis or mania. The risk was highest for those taking…
Knowingly Taking Placebos Reduces Stress and Anxiety
Summary: Researchers have discovered that nondeceptive placebos—placebos given with the full knowledge that they are placebos—can effectively manage stress, even when administered remotely. In a two-week randomized controlled trial, participants…
High-Dose Psilocybin Shows Potential as an Antidepressant Treatment
Summary: A meta-analysis suggests that high doses of psilocybin may alleviate depressive symptoms similarly to the SSRI drug escitalopram. While the effect size was small, psilocybin outperformed placebo in clinical…
Cannabigerol (CBG) Reduces Anxiety and Improves Memory
Summary: A new study shows that Cannabigerol (CBG) significantly reduces anxiety without the intoxicating effects of THC. The clinical trial found that 20 mg of CBG reduced anxiety and stress…
Mind-Bending: Psilocybin Reshapes Brain Networks for Weeks
Summary: A new study reveals that psilocybin, the active compound in magic mushrooms, temporarily disrupts brain networks involved in introspective thinking, like daydreaming and memory. These changes persist for weeks,…
Surge in Microdosing Interest Linked to Relaxed Drug Policies
Summary: A new study reveals a 1250% increase in Google searches for micro dosing from 2015 to 2023, driven by relaxed regulations on cannabis and psychedelics. The research shows policy…
Peptide Improves Cognition in Schizophrenia
Summary: Researchers developed a novel peptide, KS-133, to target cognitive dysfunction in schizophrenia. By using a brain-targeting peptide, KS-487, they successfully transported KS-133 across the blood-brain barrier. Their nanoparticle-based drug…
MDMA Variants Show Promise for Safer Psychotherapy
Summary: Researchers developed three new MDMA variants (ODMA, TDMA, and SeDMA) that retain the therapeutic benefits while reducing side effects. These compounds affect mood-regulating brain structures similarly to MDMA but…
